| Literature DB >> 35865977 |
Marina Junqueira Clemente1, Anderson Sousa Martins Silva1,2, Maria Olivia Pozzolo Pedro2, Henrique Soares Paiva2, Cintia de Azevedo Marques Périco1,3, Julio Torales4, Antonio Ventriglio5, João Maurício Castaldelli-Maia1,2,3,6.
Abstract
There is a relative dearth of research on Obsessive-Compulsive Personality Disorder (OCPD), even if it has been recognized for over 100 years. Thus, the present study aims to review the worldwide prevalence of OCPD in different populations. The search was conducted employing the PubMed database of the US National Library of Medicine and Biblioteca Virtual em Saúde (BVS) to detect available studies showing OCPD prevalence rates. All the prevalence rates were extracted and aggregated through random-effects models. Meta-regression and sensitivity analyses were performed. The final sample was composed of 46 articles, including 89,264 individuals. We found that OCPD reports a high prevalence rate, with 6.5% (95%CI = 4.3-9.1%), and reaching even higher among psychiatric and clinical patient population. OCPD has presented stable prevalence rates worldwide throughout the past 28 years. There was no gender-related effect, but OCPD prevalence rates may decrease with age increase. There is a need to investigate personality disorders epidemiology based on the recently updated classification systems (i.e., DSM-5 and ICD-11). The present meta-analysis may suggest that the current diagnostic tools may detect OCPD in a cross-sectional assessment but not throughout the life of the person.Entities:
Keywords: Compulsive personality disorder; OCPD; Personality disorders; Prevalence
Year: 2022 PMID: 35865977 PMCID: PMC9294057 DOI: 10.1016/j.heliyon.2022.e09912
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1PRISMA checklist.
Figure 2MOOSE checklist.
Results of the quality assessment.
| Authors | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Torgersen S et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Jackson JH et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Lenzenweger MF et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Coid J et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Samuels J et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Mike A et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 8 |
| Chamberlain SR et al. | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 6 |
| Jalenques I et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Gawda B el at | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Ansari Z et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Nicoletti et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Quirk SE et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Kayhan F el at | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Black DW et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Yılmaz A et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Dereboy C et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Sahingöz M et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Uguz F et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Kempke S et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Samuel DB et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Moore EA et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 8 |
| Coolidge FL et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 8 |
| Sassoon SA et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Cheng H et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Crawford TN et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Moldin SO et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 8 |
| Maier W et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Black DW et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Aycicegi-Dinn A et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| ECHEBURÚA E et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Yang M et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Torres AR et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Larsson JO et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Anderluh MB et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Sinha BK et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Maggini C et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Moran P et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Bodlund O et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Ames A et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Samuels JF et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Moran P et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Grant BF et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Wongpakaran N et al. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| HYUN HA J et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Kulkarni RR et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Ekselius L. et al. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| 1 = Yes | 0 = No/Unclear | |||||||||
Figure 3Publication Bias: Results of funnel plot and tests for all studies included in the meta-analysis for OCPD prevalence. Egger's regression test of funnel plot asymmetry: t = 2.2603, df = 75, p-value = 0.02671. Fail-safe N Calculation Using the Orwin Approach: 1 (Average Effect Size: 0.139; Target Effect Size: 0.0695).
Figure 4Study's selection flow chart.
Main results of the included studies.
| Author, year | Study population | Specific population assessed | Setting | Diagnostic criteria, | Prevalence, |
|---|---|---|---|---|---|
| N: 2053 | N: 2053 | Community | DSM III-R/SCID-II | 2.00% | |
| N: 10641 | N: 10641 | Community | CID-10/IPDE | 3.09% | |
| N: 5692 | N: 214 | Community | DSM-IV/IPDE | 2.40% | |
| N: 626 | N: 626 | Community | DSM-IV/SCID-II | 1.90% | |
| N: 742 | N: 742 | Community | DSM-IV and CID 10/IPDE | DSM-IV: UP = 1,2 (0.4), WP = 0,9 (0,5)/CID-10: UP = 1,1 (0.4), WP = 0,8 (0,4) | |
| N: 1630 | N: 1630 | Community | DSM-5/SIDP | 2.90% | |
| N: 1323 | N: 1323 | Community | DSM-5/OPQ | 71.50% | |
| N: 178 | N - Healthy Comparison Subjects (HCS): 118 | Community | DSM-IV/PDQ-4+ | 6% | |
| N - Lupus patients: 60 | Ambulatory | DSM-IV/PDQ-4+ | 13% | ||
| N: 1460 | N: 1460 | Community | DSM-IV/SCID-II | 9.66% | |
| N: 110 | N: 110 | Students | DSM-IV/SCID-II | 16.36% | |
| N: 65 | N - HCS: 20 | Community | DSM-IV/SCID-II and SCID-II-PQ | 10% | |
| N - Patients with Multiple Systems Atrophy: 15 | Ambulatory | DSM-IV/SCID-II and SCID-II-PQ | 13.3% | ||
| N - Patients with Progressive Supranuclear Palsy: 14 | Ambulatory | DSM-IV/SCID-II and SCID-II-PQ | 35.7% | ||
| N: 768 | N - Essential Tremor Patients: 16 | Ambulatory | DSM-IV/SCID-II and SCID-II-PQ | 12.5% | |
| N: 205 | N: 768 | Community | DSM-IV/SCID-II and SCID-II-PQ | 10.30% | |
| N - HCS: 100 | Community | DSM III-R/SCID-II | 8% | ||
| N: 579 | N - Chronic migraine patients: 105 | Ambulatory | DSM III-R/SCID-II | 50.50% | |
| N - HCS: 91 | Community | DSM-IV/SIDP | 3% | ||
| N - Patients diagnosed with pathological gambling: 93 | Ambulatory | DSM-IV/SIDP | 10% | ||
| N: 187 | N - 1st degree relatives of patients diagnosed with pathological gambling: 395 | Community? | DSM-IV/- | - | |
| N - HCS: 90 | Community | DSM-III-R | 6.60% | ||
| N: 774 | N - Asthmatic patients: 97 | Ambulatory | DSM-III-R | 11.34% | |
| N: 146 | N: 774 | Community | DSM-IV/CID-10 | DSM-IV = 14,1% | |
| N - HCS: 73 | Community | DSM-IV/SCID-II | 1.40% | ||
| N: 105 | N - Polycystic Ovary Syndrome Patient: 73 | Ambulatory | DSM-IV/SCID-II | 8.20% | |
| N - HCS: 60 | Community | DSM-III/SCID-II | 1.70% | ||
| N: 276 | N - Lupus patients: 45 | Ambulatory | DSM-III/SCID-II | 20.00% | |
| N: 536 | N - HCS: 92 | Community | DSM-IV/ADP-IV | 7.60% | |
| N: 1121 | N - Patients with chronic fatigue syndrome: 92 | Ambulatory | DSM-IV/ADP-IV | 8.70% | |
| N - General psychiatric patients: 92 | Ambulatory | DSM-IV/ADP-IV | 25% | ||
| N: 1569 | N: 536 | Students | DSM-IV/PDQ-4+ and SCID-II PQ | 50.40% | |
| N - HCS: 572 | Community | CID-10/IPDEQ | 20.80% | ||
| N - Schizophrenic/schizoaffective patients: 549 | Ambulatory | CID-10/IPDEQ | 35.60% | ||
| N: 59 | N - Women not incarcerated: 523 | Community | DSM-IV/CCI | 43% | |
| N - Incarcerated men: 523 | Prison | DSM-IV/CCI | 21% | ||
| N: 7675 | N - Incarcerated women: 523 | Prison | DSM-IV/CCI | 25% | |
| N: 1360 | N - HCS: 26 | Community | DSM-IV/SCID-II | 0% | |
| N: 302 | N - Women with severe pre-mental disorder: 33 | Ambulatory | DSM-IV/SCID-II | 18% | |
| N: 452 | N: 357 | Students | CID-10/PDQ-4+ and IPDE | 21.84% | |
| N: 65 | N – AGE 33: 644 | Community | DSM-IV/CIC-SR and SCID-II | CIC-SR = 1,4% e SCID II = 4,7% | |
| N: 302 | Community | DSM-III/IPDE | 1.65% | ||
| N: 117 | N: 452 | Community | DSM-III/SCID-II | 2.20% | |
| N: 381 | N - HCS: 33 | Community | DSM-III/SCID-II | 6.10% | |
| N - OCD patients: 32 | Ambulatory | DSM-III/SCID-II | 28.10% | ||
| N: 117 | Students | DSM-IV/PDQ-4+ | 17.94% | ||
| N - HCS: 103 | Community | DSM-IV/IPDE and MCMI-II | 1.9% | ||
| N: 1014 | N - Alcohol-dependent patients: 158 | Ambulatory | DSM-IV/IPDE and MCMI-II | 12% | |
| N - Psychiatric patients without alcohol dependence: 120 | Ambulatory | DSM-IV/IPDE and MCMI-II | 9.20% | ||
| N: 8399 | N - HCS: 544 | Community | DSM-IV/SCID-II | 1.80% | |
| N - Incarcerated: 470 | Prison | DSM-IV/SCID-II | 9.40% | ||
| N - HCS: 6938 | Community | DSM-IV/SCID-II | 8.10% | ||
| N: 29 | N - OCD patients: 108 | Ambulatory | DSM-IV/SCID-II | 28.60% | |
| N - Patients with other neuroses: 1353 | Ambulatory | DSM-IV/SCID-II | 20.30% | ||
| N: 100 | N - HCS: 10 | Community | DSM-IV/DIP-Q | 10% | |
| N - Women with Eating Disorders: 19 | Ambulatory | DSM-IV/DIP-Q | 63.15% | ||
| N - HCS: 28 | Community | CID-10/MOCI | 4% | ||
| N: 293 | N - Subjects With Anorexia Nervosa: 44 | Ambulatory | CID-10/MOCI | 61% | |
| N - Subjects With Bulimia Nervosa: 28 | Ambulatory | CID-10/MOCI | 46% | ||
| N: 2889 | N: 293 | Students | DSM-III-R/CATI and MCMI-II and MMPI-PD | Women: MCMI-II:0,51%/MMPI-PD:0,51%/CATI:0,51%/Men: MCMI-II:0%/MMPI-PD:2,02%/CATI:6,06% | |
| N: 2889 | Students | DSM-III/SCID-II | 30.50% | ||
| N: 303 | N: 303 | Ambulatory | CID-10 and DSM-IV/SAP and IPDE | CID-10 = 7,9%/DSM IV = 6,3% | |
| N: 587 | N - HCS: 139 | Community | DSM-IV/DIP-Q | 9% | |
| N - General psychiatric patients: 137 | Ambulatory | DSM-IV/DIP-Q | 38% | ||
| N - Forensic psychiatric sample: 217 | Forensic Psychiatric Unit | DSM-IV/DIP-Q | 41% | ||
| N - Sample of candidates for psychotherapy: 94 | Ambulatory | DSM-IV/DIP-Q | 62% | ||
| N: 200 | N: 200 | Community | DSM-III/SIDP-R | 0.50% | |
| N: 762 | N: 762 | Community | DSM-III/SPE | 1.70% | |
| N: 2032 | N: 1943 | Community | CID-10/SAP | 5.80% | |
| N: 43093 | N: 43093 | Community | DSM-IV/AUDADIS-IV | 7.90% | |
| N: 99 | N: 99 | Students | CID-10/IPDE | 2% | |
| N: 585 | N: 585 | Community | DSM-IV/PDQ-4+ | 39.80% | |
| N: 200 | N - HCS: 100 | Community | CID-10/IPDE | 4% | |
| N: 557 | N - Patients after first Suicide Attempt: 100 | Hospital | CID-10/IPDE | 11% | |
| N: 557 | Community | CID-10 and DSM-IV/DIP-Q | DSM-IV = 7,7%/ICD-10 = 7,2% |
Note. (∗) PD scale abbreviations are shown in Table 4. Additionally, the font size was reduced to fit the page.
Results of the meta-regression model for OCPD prevalence.
| Estimate | 95%CI | z | p | ||
|---|---|---|---|---|---|
| 0.001 | -0.007 | 0.009 | 0.225 | 0.822 | |
| -0.005 | -0.010 | 0.000 | -2.105 | 0.035 | |
| -0.028 | -0.247 | 0.191 | -0.253 | 0.800 | |
| -0.042 | -0.115 | 0.032 | -1.112 | 0.266 | |
| 0.177 | 0.031 | 0.322 | 2.381 | 0.017 | |
| 0.174 | -0.022 | 0.369 | 1.743 | 0.081 | |
| 0.282 | 0.133 | 0.431 | 3.702 | <0.001 | |
| -0.005 | -0.220 | 0.211 | -0.041 | 0.967 | |
| -0.055 | -0.321 | 0.210 | -0.409 | 0.683 | |
| 0.019 | -0.097 | 0.135 | 0.321 | 0.748 | |
| 0.107 | -0.134 | 0.349 | 0.871 | 0.384 | |
| 0.581 | 0.055 | 1.106 | 2.166 | 0.030 | |
| 0.018 | -0.360 | 0.396 | 0.095 | 0.925 | |
| -0.039 | -0.164 | 0.085 | -0.621 | 0.535 | |
| -0.013 | -0.183 | 0.158 | -0.144 | 0.886 | |
| -0.070 | -0.293 | 0.153 | -0.616 | 0.538 | |
Figure 5Adjusted Forest Plot. P.S.: Different subpopulation numbers (e.g., Psychiatric 1 and 2; Prison 1 and 2) refer to different type of subpopulations assessed in the same study (i.e., case-control design).
Figure 6Subgroup analysis - population
Figure 7Subgroup analysis - region
Figure 8Subgroup analysis - criterion
Methodological characteristics and geographic locations of the studies (N = 46).
| Variable | No. of Studies |
|---|---|
| Geographic location | |
| North America | 15∗ |
| Europe | 22 |
| Asia | 5 |
| South America | 0 |
| Oceania | 4 |
| Africa | 1∗ |
| Origin of Sample | |
| Community | 39 |
| Students | 7 |
| Diagnostic criteria | |
| ICD-10 | 11∗ |
| DSM-5 | 2 |
| DSM-IV | 26∗ |
| DSM-III | 11 |
| Decades | |
| 1900 | 6 |
| 2000 | 20 |
| 2010 | 20 |
Note. (∗) indicates studies that included more than one geographic locality and studies that included more than one diagnostic criterion, as explained in methodology.
Figure 9Leave-one-out